Brainsway Stock Today
| BRSYF Stock | USD 3.15 0.00 0.00% |
Performance9 of 100
| Odds Of DistressLess than 9
|
BrainsWay is trading at 3.15 as of the 27th of November 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 3.15. BrainsWay has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for BrainsWay are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. The company has 33.08 M outstanding shares. More on BrainsWay
Moving together with BrainsWay Pink Sheet
Moving against BrainsWay Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BrainsWay Pink Sheet Highlights
| President | Avner Hagai |
| Business Concentration | Medical Devices, Healthcare (View all Sectors) |
BrainsWay [BRSYF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.72 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BrainsWay's market, we take the total number of its shares issued and multiply it by BrainsWay's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BrainsWay classifies itself under Healthcare sector and is part of Medical Devices industry. The entity has 33.08 M outstanding shares.
BrainsWay has accumulated about 52.45 M in cash with 884 K of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.5.
Check BrainsWay Probability Of Bankruptcy
Ownership AllocationBrainsWay holds a total of 33.08 Million outstanding shares. BrainsWay shows 19.83 percent of its outstanding shares held by insiders and 1.11 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BrainsWay Ownership Details
BrainsWay Risk Profiles
| Mean Deviation | 1.49 | |||
| Standard Deviation | 6.15 | |||
| Variance | 37.88 | |||
| Risk Adjusted Performance | 0.1029 |
BrainsWay Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in BrainsWay without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
BrainsWay Corporate Management
| Menachem Esq | Gen VP | Profile | |
| Christopher Jako | Pres CEO | Profile | |
| Christopher Boyer | VP Marketing | Profile | |
| Hadar Levy | VP COO | Profile | |
| Moria Ankri | VP RD | Profile |
Additional Information and Resources on Investing in BrainsWay Pink Sheet
When determining whether BrainsWay offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BrainsWay's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainsway Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainsway Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.